MXPA04001913A - Metodos para reducir la hipertension y falla cardiaca. - Google Patents

Metodos para reducir la hipertension y falla cardiaca.

Info

Publication number
MXPA04001913A
MXPA04001913A MXPA04001913A MXPA04001913A MXPA04001913A MX PA04001913 A MXPA04001913 A MX PA04001913A MX PA04001913 A MXPA04001913 A MX PA04001913A MX PA04001913 A MXPA04001913 A MX PA04001913A MX PA04001913 A MXPA04001913 A MX PA04001913A
Authority
MX
Mexico
Prior art keywords
heart
tyrphostin
hypertrophy
ischemia
set forth
Prior art date
Application number
MXPA04001913A
Other languages
English (en)
Spanish (es)
Inventor
A Q Siddiqui M
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of MXPA04001913A publication Critical patent/MXPA04001913A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA04001913A 2001-08-31 2002-07-23 Metodos para reducir la hipertension y falla cardiaca. MXPA04001913A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/945,192 US6433018B1 (en) 2001-08-31 2001-08-31 Method for reducing hypertrophy and ischemia
PCT/US2002/023444 WO2003020202A2 (en) 2001-08-31 2002-07-23 Method for reducing hypertension and heart failure

Publications (1)

Publication Number Publication Date
MXPA04001913A true MXPA04001913A (es) 2004-06-18

Family

ID=25482762

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001913A MXPA04001913A (es) 2001-08-31 2002-07-23 Metodos para reducir la hipertension y falla cardiaca.

Country Status (11)

Country Link
US (2) US6433018B1 (OSRAM)
EP (1) EP1427401A4 (OSRAM)
JP (2) JP2005505545A (OSRAM)
KR (1) KR20040050894A (OSRAM)
AU (1) AU2002313700B2 (OSRAM)
BR (1) BR0212252A (OSRAM)
CA (1) CA2458798C (OSRAM)
MX (1) MXPA04001913A (OSRAM)
NZ (1) NZ531693A (OSRAM)
WO (1) WO2003020202A2 (OSRAM)
ZA (1) ZA200402540B (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20050038450A1 (en) * 2003-06-03 2005-02-17 Ping Hu Methods and apparatus for minimally invasive transverse aortic banding
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
US20050130893A1 (en) * 2003-09-30 2005-06-16 Joan Smith-Sonneborn Use of opioids in prevention of and recovery from a stress-induced crash in blood pressure
PT1701941E (pt) 2003-12-11 2012-08-03 Univ Texas Compostos para o tratamento de doenças proliferativas celulares
US7662389B2 (en) * 2003-12-17 2010-02-16 Alcon, Inc. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US20100113481A1 (en) * 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
US8691877B2 (en) * 2004-10-15 2014-04-08 Palo Alto Investors Methods and compositions for treating a disease condition in a subject
EP1904457B1 (en) 2005-06-08 2017-09-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US10517876B2 (en) 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
ES2506040T3 (es) 2005-11-16 2014-10-13 Cti Biopharma Corp. Derivados de pirimidina ligados a oxígeno
CA2637044A1 (en) * 2006-01-13 2007-07-26 President And Fellows Of Harvard College Xenohormesis based compositions and methods
JP2009528295A (ja) * 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
US8410173B2 (en) * 2006-02-28 2013-04-02 Ym Biosciences Australia Pty Ltd Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
PL2514742T3 (pl) * 2006-03-31 2015-07-31 Univ Texas Leki przeciwnowotworowe będące pochodnymi kwasu kawowego dostępnymi biologicznie po podaniu doustnym
US8486941B2 (en) 2007-03-12 2013-07-16 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
HUE030912T2 (en) 2008-02-15 2017-06-28 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
US8138339B2 (en) * 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
JP5675606B2 (ja) 2008-07-08 2015-02-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム シグナル伝達性転写因子（ｓｔａｔ）の増殖及び活性化の新規の抑制剤
SG171907A1 (en) 2008-12-11 2011-07-28 S Bio Pte Ltd 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
CA2768543C (en) * 2009-07-28 2017-06-20 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP5275966B2 (ja) * 2009-12-21 2013-08-28 パナソニック株式会社 繊維ボードの製造方法
EP2635557A2 (en) 2010-11-01 2013-09-11 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
SG11201402570QA (en) 2011-11-23 2014-06-27 Portola Pharm Inc Pyrazine kinase inhibitors
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
TWI729644B (zh) 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2012634A1 (en) * 1990-03-20 1991-09-20 Hassan Salari Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US6255296B1 (en) 1994-01-11 2001-07-03 Endomatrix, Inc. Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
US6358954B1 (en) * 1999-11-09 2002-03-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
US6433018B1 (en) * 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
DE602006000402T8 (de) * 2006-06-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Stabile Zubereitung enthaltend eine feuchtigkeitsempfindliche aktive Substanz und Verfahren zur Herstellung der Zubereitung.

Also Published As

Publication number Publication date
CA2458798A1 (en) 2003-03-13
ZA200402540B (en) 2005-06-29
US6433018B1 (en) 2002-08-13
BR0212252A (pt) 2004-09-14
WO2003020202A3 (en) 2003-08-28
NZ531693A (en) 2006-05-26
EP1427401A2 (en) 2004-06-16
JP2005505545A (ja) 2005-02-24
AU2002313700B2 (en) 2007-04-26
JP2010285455A (ja) 2010-12-24
CA2458798C (en) 2013-06-25
WO2003020202A2 (en) 2003-03-13
US7235588B2 (en) 2007-06-26
EP1427401A4 (en) 2009-04-29
KR20040050894A (ko) 2004-06-17
US20040266661A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
AU2002313700B2 (en) Method for reducing hypertension and heart failure
AU2002313700A1 (en) Method for reducing hypertension and heart failure
Schrör et al. Beneficial effects of a new carbacyclin derivative, ZK 36 374, in acute myocardial ischemia.
Dell'italia et al. Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs
US20090209473A1 (en) Componds and methods for pormoting angiogenesis
JP2003238445A (ja) 心肥大のための処置としてのヒストンデアセチラーゼの阻害
JP2001502292A (ja) Ｐｄｇｆアンタゴニストとしての４−〔２−（ｎ−２−カルボキサミドインドール）アミノエチル〕ベンゼンスルホンアミドまたはスルホニル尿素
KR20010031179A (ko) 레닌-안지오텐신 시스템 억제제의 용도
EP3419666A1 (en) Alpha-1-adrenergic receptor agonist therapy
Ikegaki et al. Involvement of Rho-kinase in vascular remodeling caused by long-term inhibition of nitric oxide synthesis in rats
US20070219180A1 (en) Muscle Relaxtion Accelerator and Therapeutic Agent for Muscular Tissue Diseases Such as Muscle Relaxation Failure
CN103429242A (zh) 用于预防和治疗心脏肥大的方法和组合物
US20250387390A1 (en) Methods for treating fibrosis using pkm2 activators
Tsutsui et al. Significance of nitric oxide derived from the nitric oxide synthases system in cardiovascular interorgan crosstalk
KR102564240B1 (ko) 선택적 히스톤탈아세틸화 효소 8 억제제를 포함하는 심장 질환 예방 또는 치료용 조성물
JP2003531114A (ja) プロテインキナーゼα阻害剤の使用
Gao et al. Remote Postconditioning Cardio-protection After Myocardial Ischemia/reperfusion Injury by Eliminating 4-HNE and Regulating Autophagy Through ALDH2/SIRT3/HIF1α Signaling Pathway
TW202529758A (zh) 用於治療疾病及病症之ｈｄａｃ６選擇性抑制劑
JP2025502209A (ja) うっ血性心不全の処置
CN121337997A (zh) α-半乳糖苷酶抑制剂在制备治疗心肌损伤相关疾病药物中的应用
Al-Yasseri A study of the cardio-protective effect of Pioglitazone, MgSO4 and Omega-3 fatty acids in rabbits after induction of acute myocardial infarction
Barnes The molecular mechanisms underlying cardiac hypertrophy due to volume overload.
US20170128398A1 (en) Gentisic acid is used to improve systemic hemodynamics, hepatic mitochondrial function and lactate acidemia in patients with septic shock
Fitch Evaluation of the role of nitric oxide synthase in the regulation of aortic stiffness
Lee et al. Final Accepted Version Effect of Pravastatin on Left Ventricular Mass in the Two-Kidney, One Clip Hypertensive Rats

Legal Events

Date Code Title Description
FG Grant or registration